Aim: Alterations of cerebral blood flow have been reported in studies of depression treated by transcranial magnetic stimulation (TMS). However, the relation between these changes in activity during stimulation and the effectiveness of TMS is not known. The aim of this study was to determine whether changes in frontal cerebral blood volume measured as frontal hemoglobin concentration (fHbC) during TMS are correlated with clinical outcomes of treatment.
T RANSCRANIAL MAGNETIC STIMULATION (TMS) delivered in a standardized highfrequency pulse sequence to the left dorsolateral prefrontal cortex (DLPFC) is a safe and effective treatment for patients with major depressive disorder who have not received benefit from antidepressant medication. [1] [2] [3] [4] [5] Although the clinical application of TMS as an antidepressant is well established in randomized clinical trials, the exact biological mechanism underlying its clinical effectiveness is not well understood. The present study intended to examine the role of frontal cerebral hemodynamic change during stimulation in the clinical effectiveness of TMS. Previous reports on depression have shown that TMS applied to the left DLPFC modulates cerebral blood flow (CBF) in several brain regions, including the frontal cortex. [6] [7] [8] Based on these findings, studies have investigated the relation between changes in brain metabolic activity and treatment effectiveness. The antidepressant effects of TMS are associated with functional changes in the frontal brain, as well as changes in functional connectivity among the regions, including the frontal cortex. 9 ,10 TMS nonresponders also showed significant hypoperfusion in the superior frontal cortices (Brodmann area 10) compared to responders. 11 These findings indicate that frontal CBF changes are related to treatment efficacy in depression. However, in most studies, data have been collected before and after the stimulation. Monitoring these measurements during stimulation is important given that primary changes in these systems could be related to treatment effectiveness. Although in several studies, CBF was measured during TMS in healthy subjects, 12 the relation between these measurements and clinical efficacy in the treatment of depression has yet to be determined.
In the present study, it was hypothesized that CBF change in the frontal cortex during stimulation is related to amelioration of symptoms. We used nearinfrared spectroscopy (NIRS) to measure frontal cerebral hemoglobin concentration (fHbC) reflecting cerebral blood volume during stimulation and assessed the relation with treatment effectiveness. NIRS is a non-invasive method to assess CBF by measuring hemoglobin concentration using nearinfrared light absorption in the brain, and has been widely applied to mental disorders, including depression. 13 Although spatial resolution is less precise in NIRS in comparison with other techniques, including functional magnetic resonance imaging and single-photon emission computed tomography, NIRS has the advantage in the temporal resolution and was adequate for simultaneous measurement with magnetic stimulation in the present study. The results support the usefulness of fHbC measurement during TMS for evaluating its clinical effectiveness.
METHODS Subjects
Fifteen subjects who had been diagnosed with major depressive disorder according to the DSM-IV 14 and who sought treatment at Maynds Tower Mental Clinic, Tokyo, Japan, participated consecutively in the present pilot study (mean age AE SD, 45.4 AE 10.8 years; 11 men, four women; all were right-handed). Patients who had neurological disorders or other psychiatric disorders were excluded from the study. The age of onset, the duration of illness, and the number of depressive episodes were 38.7 AE 9.6 years, 6.7 AE 4.5 years, and 1.2 AE 0.6, respectively. Depression symptoms were evaluated using the Montgomery-Åsberg Depression Rating Scale (MADRS), 15 and the mean score of the patients was 24.1 AE 8.0 at the start of the TMS treatment. After the treatment, the score decreased to 10.2 AE 7.9. Eleven patients showed a decrease by 10 points or more, but none was completely free from depressed symptoms. The reduction rate in the MADRS score was calculated as the difference between the MADRS score at the start and the end of treatment divided by the MADRS score at the start (100 × [start -end] / start), and was 59.5 AE 23.7%.
According to clinical history, all patients recruited for this study had failed to receive sufficient clinical benefit from treatment with multiple types of antidepressant medications for more than a year, and were therefore considered to be treatment resistant. Benzodiazepines were also used in some cases due to symptomatic severity during TMS treatment; the patients continued to take their currently prescribed antidepressant or antianxiety medications without any change in dose (89.6 AE 85.8 mg [fluvoxamineequivalent] and 5.9 AE 6.4 mg [diazepam-equivalent], respectively). [16] [17] [18] Six patients were not taking antidepressants at the time of the TMS treatment series.
All study procedures were reviewed and approved by the Institutional Review Board of Maynds Tower Mental Clinic. All subjects signed informed consent before any study procedures were performed.
TMS procedures
All TMS treatments were performed with the NeuroStar TMS Therapy System (Neuronetics, Inc., Malvern, PA, USA). Stimulation was performed according to standard procedures as described in the product documentation. During the initial treatment session, the location of the motor strip was identified by single-pulse stimulation, with specific identification of the location for movement of the contralateral thumb. Motor threshold (MT) was obtained using an automated algorithm (MT Assist, Neuronetics, Inc.). The mean MT in all patients was 1.25 AE 0.18 standard motor threshold (SMT; a unit used for stimulation intensity in NeuroStar). The stimulation site at the left DLPFC was then identified by advancing the coil 5.5 cm anterior to the MT location, using a mechanical head-support system, along a parasagittal line with a rotation point centered about the patient's nose. Treatment parameters were standardized for each session at the treatment location with a magnetic field intensity of 120% of MT, at a pulse frequency of 10 pulses/s, with a 4-s on time and a 26-s off time for a total exposure of 3000 pulses per session. Each treatment took 37.5 min and was performed 5 days per week for 6 weeks for a total of 30 treatments (Fig. 1 ).
NIRS measurement
On the first (start) and last (end) day of the TMS treatment series ( Fig. 1) , fHbC was monitored while the stimulation session was underway. Data were obtained continuously within the 37.5-min TMS session with the treatment session being uninterrupted for these assessments. We assessed fHbC by measuring oxygenated hemoglobin (oxyHb) using continuous-wave NIRS with the projection and detection probes separated by 5 cm on the forehead (two white circles in Fig. 1 , NIRO-300, Hamamatsu Photonics, Hamamatsu, Japan). The center of the probes was set at Fpz, and the separation interval of the probes was 5 cm to cover bilateral frontal poles. 19 The NIRS apparatus uses three wavelengths of near-infrared light. The path length was set at 30 cm and the oxyHb index was calculated using the following equation: oxyHb concentration × 30 (M × cm). 19 The fHbC response to TMS was calculated as the difference between the averaged oxyHb index during stimulation and the average of 1-min pre-stimulation baseline data (horizontal line, Fig. 2 ).
Because the path length in the continuous-wave NIRS measurement is not known and was set at 30 cm in the present study, the difference from the real path length may have lessened the credibility of the data. However, the direction of the fHbC response during TMS, positive or negative, with reference to the baseline is not affected by the path length, and actually varied depending on the TMS session (Fig. 3a) ; fHbC increased during some stimulations (fHbC increase) and reduced during others (fHbC decrease). At the initial session, most of the patients showed fHbC increase during stimulation. On the other hand, the fHbC decrease pattern was observed more at the end of the treatment series. In the present study, we divided the patients into two groups with different directions of changes at the end of the treatment series: the HbC increase group and the fHbC decrease group.
Statistical analysis
The data were analyzed after TMS treatment was over. Spearman's correlation coefficients were used to identify possible correlations between fHbC and MADRS scores to test whether the former were related to clinical outcome. The difference in MADRS scores, MT levels, medications, and other demographic data between the fHbC increase and decrease groups were checked using the Student's t-test or Fisher's test (Prism5, GraphPad Software, La Jolla, CA, USA). The alpha level of the statistics was set at 0.05. Normal distribution of the data was confirmed by Kolmogorov-Smirnov normality test when the Student's t-test was used (P > 0.1). Cohen's d (d) was calculated to examine the effect size.
RESULTS
Relation between fHbC during stimulation and MADRS score Figure 4 shows the correlation between the fHbC response and the MADRS score. There was no significant correlation between the fHbC response and 
MADRS scores in the fHbC increase and decrease groups
In the present study, the subjects were divided into two groups (fHbC increase or fHbC decrease) based on the fHbC response during stimulation at the end of the TMS treatment series (Fig. 3a) . At the start of the series, the majority of the subjects showed an increase in fHbC during stimulation. At the end of the series, some patients maintained an increased fHbC response (fHbC increase group, n = 9), whereas other patients exhibited a decreased fHbC response during stimulation (fHbC decrease group, n = 6). Table 1 summarizes the demographic, NIRS, and MADRS data. The fHbC responses during TMS of both groups were statistically different at the end of the treatment series (P < 0.001), but not at the start (P > 0.05). The difference between the fHbC at the start and end in the decrease group (end -start) was significantly larger than that in the increase group (P < 0.001). There were no significant differences in age, sex, or MT level between the two groups (P > 0.05, Table 1 ). The MADRS score at the beginning and end of the treatment in the fHbC increase group was significantly lower than that in the decrease group (t = 2.787, P = 0.015, d = 1.21 and t = 3.301, P = 0.006, d = 1.33, respectively). The score reduction rate in the MADRS at the end of the treatment series was significantly greater in the fHbC increase group compared to the fHbC decrease group (Fig. 3, B , P = 0.030, d = 1.10).
Medication
As for the daily use of medication, fluvoxamineequivalent doses of antidepressants and diazepamequivalent of doses of antianxiety drugs were calculated based on the clinical doses recommended by the manufacturers (Table 1) . [16] [17] [18] There was no significant difference between the two groups (P > 0.05).
DISCUSSION Frontal activation during TMS and treatment effectiveness
Previous studies have shown that TMS induces increase in CBF after a series of stimulation sessions. 7, 20 However, in these studies, post-TMS CBF was measured more than 1 day after the end of the treatment series. The present study is unique in assessing CBF during stimulation. Moreover, no relation with therapeutic efficacy was observed at the initial session with a majority of the patients showing frontal activation during stimulation, but the relation became significant at the end of the treatment series (Fig. 4) . The subjects with higher frontal cerebral blood volume responses during stimulation at the end of the treatment series had lower MADRS scores and a greater reduction in MADRS score. The activation was mainly seen in the patients showing clinical recovery at the end of the treatment, and would be related to the outcome of TMS therapy. The dose of medication or the MT level had no effect on the present findings.
The results may suggest that the failure to maintain activation and the shift to deactivation of the frontal cortex during stimulation in the course of treatment are related to inability to reduce depressive symptoms by TMS, as assessed through the MADRS. It was considered that alteration of responsiveness of the frontal cortex to stimulation could be due to dysfunction of the brain in the depressed patients not responding to TMS treatment. MADRS data suggest that the failure to maintain frontal activation to TMS is related to the severity of depressive disorder at the start of the treatment series. TMS treatment may be more effective for depression with milder symptoms. Obtaining the frontal cerebral blood volume data during stimulation at the beginning and end of the treatment series can allow us to assess the pathophysiological changes of the brain in depression as well as the therapeutic efficacy and validity of TMS. Further studies with other neuronal measurements are warranted. 21 It is known that the prefrontal cortex has rich bilateral connections with various cortical and subcortical areas. 22 Stimulation of the DLPFC in the present study should activate various brain areas, including the frontal brain itself in relation to symptom recovery. The presence of activation at the end of the treatment series may suggest that the patients with greater recovery have received the ameliorative effect of TMS sufficiently during the treatment series. On the other hand, the activation may be diminished in the nonresponding patients in the course of treatment series, leading to insufficient clinical effects. This finding may be related to the previous report by Richieri et al.
11 which showed significant hypoperfusion in several brain regions of depressed patients resistant to TMS treatment, including the bilateral superior frontal cortices, although the hypoperfusion in this report was present in the prestimulation baseline state. The underlying brain mechanisms of altered activity during stimulation in the nonresponding patients of the present study should be assessed in future research with more frequent measurements in the treatment series.
In the present study, we analyzed the frontal cerebral blood volume data in two ways, correlation analysis and comparison of the mean in two groups, fHbC increase and decrease, because of the methodological limitation in continuous-wave NIRS with the path lengths unknown. 19 However, the results from the two kinds of analyses are the same and confirm our conclusions. The data regarding the fHbC increase and decrease will be interesting when the clinical usage of NIRS measurements is considered in the TMS treatment of depression, because the increase or decrease discrimination would be simple and convenient. The present results suggest that the fHbC increase and decrease groups may be grossly assimilated to responders and nonresponders, respectively. It has been reported in a positron emission tomography study that responders to treatment with antidepressant or placebo for 6 weeks showed activation in several cortical regions, including frontal areas. 23 The present finding further indicates that frontal activation is related to the therapeutic response by TMS.
Previous studies have reported that CBF could be used to predict the effectiveness of treatment. High activity in the neocortical, anterior cingulate, and limbic areas before the start of treatment is related to the TMS treatment response. [24] [25] [26] A task-related change in CBF can also predict the clinical response to TMS. 27 In addition to these pretreatment data, the present study revealed the usefulness of monitoring frontal CBF during TMS, which will lead to understanding of the direct neural response to TMS regarding the treatment outcome.
Stimulation sites and parameters
As for the stimulation parameters, the present study used TMS at a stimulation frequency of 10 Hz to the left DLPFC. A lower stimulation frequency has been shown to have different effects on regional brain activity in depressed patients. 6 High-frequency TMS leads to an overall increase, whereas low-frequency TMS produces a decrease in CBF. 8 In addition, stimulation of the right brain hemisphere 28, 29 and change in the coil orientation lead to different effects in CBF. 30 Further studies with different stimulation sites and parameters would reveal more adequate ways to use CBF to evaluate the treatment efficacy and severity of depression.
Limitations
This was a pilot study with a small number of patients and high male-to-female ratio. Future studies with a larger sample size will be important, because the individual variation could be large. It is also underlined that the results are valid for the patients who do not show sufficient improvements with antidepressant medication. Future studies are necessary to expand the assessment to depression in general.
In the present study, we only measured frontal cerebral blood volume at the start and end of the TMS treatment series, and the data in the middle of the treatment series are lacking. It was not examined in the present study whether frontal response pattern in the middle of the series was fHbC increase or decrease. Multiple fHbC measurements in the course of TMS treatment series are necessary to consolidate the interpretation of the present finding on frontal cerebral blood volume in regard to the treatment outcome. Increasing the measurement frequency is warranted in future research.
The fHbC monitoring was also limited to the anterior frontal region covering the frontal pole, one of the brain areas shown to be affected by TMS treatment. 11 Other brain areas should be assessed to further understand the relation between CBF and treatment efficacy.
As for the NIRS methods, continuous-wave spectroscopy was used in the present study as it has been frequently applied to clinical research. 19 Other NIRS methods, including time-resolved and frequencydomain spectroscopy, will be informative in future research because absolute CBF is available. 31 Other brain signals, including those detected by electroencephalography and functional magnetic resonance imaging, will be interesting to assess the change in activity during TMS as these techniques have higher spatial resolution.
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